This finding has led to studies associating LCN2 overexpression with the progression of multiple cancers and with the poor prognosis of aggressive forms of breast cancer [26], pancreatic cancer [27], and endometrial carcinoma [28]. Here, LCN2 is linked to familial pancreatic carcinoma.